Lupin launches COVID-19 drug in India at Rs 49 per tablet

Drug major Lupin on Wednesday announced the launch of its Favipiravir drug under the brand name ‘Covihalt’ for the treatment patients with mild to moderate COVID-19 symptoms at Rs 49 per tablet in India

Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use, Lupin said in a regulatory filing.

Its Covihalt dosage strength has been developed keeping in mind convenience of administration, it stated, adding that the drug is available as 200 mg tablets in the form of a strip of 10 tablets, and priced at Rs 49 per tablet.

Lupin President – India Region Formulations (IRF) Rajeev Sibal said the company believes that it can leverage its expertise in managing widespread community diseases like tuberculosis to proactively reach patients across India.

On August 4, Sun Pharmaceutical Industries had launched Favipiravir under the brand name ”FluGuard” for the treatment of mild to moderate cases of COVID-19, at Rs 35 per tablet in India.

Shares of Lupin were trading 0.32 per cent higher at Rs 943.70 apiece on BSE.

माध्यमांनी दिलेल्या माहितीनुसार कोविड१९ ची सौम्य लक्षणं दिसत असलेल्या रुग्णांना ही औषधं दिली जाणार आहेत. हे औषध फेविपिराविरचे वर्जन आहे. फेविपरिविर हे एक मात्र असं औषध आहे.ज्या औषधाला भारतात एंटी व्हायरल ट्रिटमेंटसाठी कोविड १९ च्या रुग्णांवर उपचार करण्याच

Meanwhile, in other news, doctors at a hospital here have used a new drug called RLF-100, also known as aviptadil, that has led to rapid recovery from respiratory failure in critically ill COVID-19 patients.

The drug has been approved by the FDA for emergency use at multiple clinical sites in patients who are too ill to enter the FDA's Phase 2/3 trials.